Tamarind Trypsin Inhibitor in Chitosan–Whey Protein Nanoparticles Reduces Fasting Blood Glucose Levels without Compromising Insulinemia: A Preclinical Study
| Autor: | Isabel R. Amado, Pedro Paulo de Andrade Santos, Ana Heloneida de Araújo Morais, Alexandre C. Serquiz, Rafael Oliveira de Araújo Costa, Christina da Silva Camillo, Thaís Souza Passos, Catarina Gonçalves, Lídia Leonize Rodrigues Matias, Bruna Leal Lima Maciel, Jaluza Luana Carvalho de Queiroz, Lorenzo Pastrana |
|---|---|
| Jazyk: | angličtina |
| Předmět: |
Blood Glucose
Male Whey protein 030309 nutrition & dietetics medicine.medical_treatment Regulation of gastric function digestion Tamarindus Trypsin 2. Zero hunger 0303 health sciences Nutrition and Dietetics medicine.diagnostic_test Chemistry Hydrolysis Fasting 04 agricultural and veterinary sciences 040401 food science Controlled release 3. Good health Tamarindusindica L Glycemic index Seeds Trypsin Inhibitors insulin medicine.medical_specialty Trypsin inhibitor Article 03 medical and health sciences 0404 agricultural biotechnology overfeeding In vivo Internal medicine medicine Animals Hypoglycemic Agents Rats Wistar Pancreas Chitosan Plant Extracts Insulin Cholesterol HDL Diet Whey Proteins Endocrinology Glycemic Index Delayed-Action Preparations Hyperglycemia encapsulation Nanoparticles Insulin Resistance fasting glucose Lipid profile Food Science |
| Zdroj: | Nutrients Volume 11 Issue 11 |
| ISSN: | 2072-6643 |
| DOI: | 10.3390/nu11112770 |
| Popis: | In vivo studies show the benefits of the trypsin inhibitor isolated from tamarind (Tamarindusindica L.) (TTI) seeds in satiety and obesity. In the present study, TTI nanoencapsulation (ECW) was performed to potentialize the effect of TTI and allow a controlled release in the stomach. The impact on glycemia, insulin, and lipid profile was evaluated in Wistar rats overfed with a high glycemic index diet (HGLI). Characterization of the nanoparticles and in vitro stability in simulated gastrointestinal conditions, monitored by antitrypsin activity and HPLC, was performed. ECW and empty nanoparticles (CW) were administered by gavage, using 12.5 and 10.0 mg/kg, respectively. Both nanoformulations presented a spherical shape and smooth surface, with an average diameter of 117.4 nm (24.1) for ECW and 123.9 nm (11.3) for CW. ECW maintained the antitrypsin activity (95.5%) in the gastric phase, while TTI was completely hydrolyzed. In Wistar rats, the nanoformulations significantly reduced glycemia and HOMA IR, and ECW increased HDL-c compared to CW (p < 0.05).Pancreas histopathology of animals treated with ECW suggested an onset of tissue repair. Thenanoencapsulation provided TTI protection, gradual release in the desired condition, and improvement of biochemical parameters related to carbohydrate metabolism disorders,without compromising insulinemia. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|